Feature

Stopping anti-TNF drugs in PsA has high rebound risk

Publish date: October 26, 2017

 

FROM JOURNAL OF RHEUMATOLOGY

Pages

Recommended Reading

Launch of adalimumab biosimilar Amjevita postponed
MDedge Rheumatology
TNF inhibitors associated with fewer side effects than methotrexate in children with psoriasis
MDedge Rheumatology
Ixekizumab has profound impact on genital psoriasis
MDedge Rheumatology
Genital psoriasis is the worst: Patients sound off
MDedge Rheumatology
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
MDedge Rheumatology
High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar
MDedge Rheumatology
Psoriasis: Biologics bring potential for long-term remission off treatment
MDedge Rheumatology
Golimumab earns new FDA approvals
MDedge Rheumatology
Biosimilars poised to save $54 billion over the next decade
MDedge Rheumatology
Swedish study finds low risk of developing psoriasis in bariatric surgery patients
MDedge Rheumatology

Related Articles